118 related articles for article (PubMed ID: 18937609)
1. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study.
Florentin M; Liberopoulos EN; Filippatos TD; Kostara C; Tselepis A; Mikhailidis DP; Elisaf M
Expert Opin Pharmacother; 2008 Nov; 9(16):2741-50. PubMed ID: 18937609
[TBL] [Abstract][Full Text] [Related]
2. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.
Filippatos TD; Kiortsis DN; Liberopoulos EN; Georgoula M; Mikhailidis DP; Elisaf MS
Curr Med Res Opin; 2005 Dec; 21(12):1997-2006. PubMed ID: 16368051
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
Florentin M; Kostapanos MS; Nakou ES; Elisaf M; Liberopoulos EN
J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):274-82. PubMed ID: 19724023
[TBL] [Abstract][Full Text] [Related]
4. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
[TBL] [Abstract][Full Text] [Related]
5. Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study.
Florentin M; Liberopoulos EN; Tellis CC; Derdemezis CS; Elisaf M; Tselepis A
Angiology; 2010 May; 61(4):365-71. PubMed ID: 19926622
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
8. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
Hollander P
Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
[TBL] [Abstract][Full Text] [Related]
9. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP; Golay A; Sjöström L;
N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
[TBL] [Abstract][Full Text] [Related]
10. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Després JP; Ross R; Boka G; Alméras N; Lemieux I;
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
[TBL] [Abstract][Full Text] [Related]
11. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.
Agouridis AP; Kostapanos MS; Tsimihodimos V; Kostara C; Mikhailidis DP; Bairaktari ET; Tselepis AD; Elisaf MS
Int J Clin Pract; 2012 Sep; 66(9):843-53. PubMed ID: 22897461
[TBL] [Abstract][Full Text] [Related]
12. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Keating GM; Ormrod D
Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
[TBL] [Abstract][Full Text] [Related]
13. The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.
Paragh G; Seres I; Harangi M; Balogh Z; Illyés L; Boda J; Szilvássy Z; Kovács P
Diabetes Metab; 2003 Dec; 29(6):613-8. PubMed ID: 14707891
[TBL] [Abstract][Full Text] [Related]
14. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.
Filippatos TD; Gazi IF; Liberopoulos EN; Athyros VG; Elisaf MS; Tselepis AD; Kiortsis DN
Atherosclerosis; 2007 Aug; 193(2):428-37. PubMed ID: 16911813
[TBL] [Abstract][Full Text] [Related]
15. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
[TBL] [Abstract][Full Text] [Related]
16. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.
Agouridis AP; Tsimihodimos V; Filippatos TD; Dimitriou AA; Tellis CC; Elisaf MS; Mikhailidis DP; Tselepis AD
Expert Opin Pharmacother; 2011 Dec; 12(17):2605-11. PubMed ID: 21714585
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
Kiortisis DN; Millionis H; Bairaktari E; Elisaf MS
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):631-5. PubMed ID: 11214768
[TBL] [Abstract][Full Text] [Related]
18. The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide.
Achimastos A; Liberopoulos E; Nikas S; Bairaktari E; Miltiadous G; Tsimihodimos V; Elisaf M
Curr Med Res Opin; 2002; 18(2):59-63. PubMed ID: 12017210
[TBL] [Abstract][Full Text] [Related]
19. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
Ruilope LM; Després JP; Scheen A; Pi-Sunyer X; Mancia G; Zanchetti A; Van Gaal L
J Hypertens; 2008 Feb; 26(2):357-67. PubMed ID: 18192851
[TBL] [Abstract][Full Text] [Related]
20. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome.
Filippatos TD; Liberopoulos EN; Kostapanos M; Gazi IF; Papavasiliou EC; Kiortsis DN; Tselepis AD; Elisaf MS
Diabetes Obes Metab; 2008 Jun; 10(6):476-83. PubMed ID: 17459096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
